Top

Published in:

Open Access 01-06-2018 | Review

A Review of Meningococcal Disease and Vaccination Recommendations for Travelers

Authors: Lidia C. Serra, Laura J. York, Amgad Gamil, Paul Balmer, Chris Webber

Published in: Infectious Diseases and Therapy | Issue 2/2018

Abstract

International travel has been steadily increasing since the middle of the twentieth century, including travel to regions with high levels of endemic meningococcal disease and areas with sporadic or sustained meningococcal outbreaks. Although invasive meningococcal disease (IMD) is relatively rare in travelers since the advent of quadrivalent meningococcal vaccines, it remains a serious concern because of its rapid progression, poor prognosis and outcomes, associated treatment delays, and the potential to precipitate outbreaks. Moreover, fatality occurs in up to 22% of those infected. This review will focus on IMD in travelers, with an emphasis on IMD epidemiology and the geographic regions of potential concern for international travelers. As vaccination is the best approach for preventing IMD among travelers, currently available meningococcal vaccines and corresponding country-specific national meningococcal vaccination recommendations, where available, will be summarized by age and type of vaccine recommended. The use of the quadrivalent meningococcal vaccines, specifically the tetanus toxoid conjugate vaccine (including MenACWY-TT; Nimenrix^®), as a protective measure against IMD in travelers will be emphasized.

Funding

Pfizer Inc.

World Tourism Organization. UNWTO tourism highlights, 2016. Available at: http://www.e-unwto.org/doi/pdf/10.18111/9789284418145. Accessed November 2, 2017.

Wilder-Smith A. Meningococcal disease in travelers: a rare but devastating disease. J Travel Med. 2010;17(suppl):1–2.CrossRefPubMed

Pelton SI. The global evolution of meningococcal epidemiology following the introduction of meningococcal vaccines. J Adolesc Health. 2016;59(suppl):S3–11.CrossRefPubMed

von Gottberg A, du Plessis M, Cohen C, et al. Emergence of endemic serogroup W135 meningococcal disease associated with a high mortality rate in South Africa. Clin Infect Dis. 2008;46:377–86.CrossRef

Centers for Disease Control and Prevention. Meningococcal disease. Available at: http://www.cdc.gov/vaccines/pubs/pinkbook/downloads/mening.pdf. Accessed March 23, 2017.

Swartz MN. Bacterial meningitis—a view of the past 90 years. N Engl J Med. 2004;351:1826–8.CrossRefPubMed

Pace D, Pollard AJ. Meningococcal disease: clinical presentation and sequelae. Vaccine. 2012;30(suppl 2):B3–9.CrossRefPubMed

Jafri RZ, Ali A, Messonnier NE, et al. Global epidemiology of invasive meningococcal disease. Popul Health Metr. 2013;11:11–7.CrossRef

Cohn AC, MacNeil JR, Clark TA, et al. Prevention and control of meningococcal disease: recommendations of the Advisory Committee on Immunization Practices (ACIP). MMWR Recomm Rep. 2013;62:1–28.PubMed

10.

European Medicines Agency. Annex 1: summary of product characteristics (Nimenrix). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/002226/WC500127663.pdf, 2017. Accessed March 9, 2018.

11.

Safadi MA, O’Ryan M, Valenzuela Bravo MT, et al. The current situation of meningococcal disease in Latin America and updated Global Meningococcal Initiative (GMI) recommendations. Vaccine. 2015;33:6529–36.CrossRefPubMed

12.

World Health Organization. Meningococcal disease in countries of the African meningitis belt, 2012-emerging needs and future perspectives. Wkly Epidemiol Rec. 2013;88:129–36.

13.

World Health Organization. Control of epidemic meningococcal disease. WHO practical guidelines. 2nd edition. Available at: http://www.who.int/csr/resources/publications/meningitis/whoemcbac983.pdf. Accessed November 2, 2017.

14.

LaForce FM, Okwo-Bele J-M. Eliminating epidemic group A meningococcal meningitis in Africa through a new vaccine. Health Aff (Millwood). 2011;30:1049–57.CrossRef

15.

MenAfriVac (meningococcal A conjugate vaccine). Full prescribing information, Serum Institute of India, Pune, India, 2015.

16.

Djingarey MH, Barry R, Bonkoungou M, et al. Effectively introducing a new meningococcal A conjugate vaccine in Africa: the Burkina Faso experience. Vaccine. 2012;30(suppl 2):B40–5.CrossRefPubMed

17.

World Health Organization. Meningitis weekly bulletin, inter country support team—West Africa. Available at: http://www.meningvax.org/epidemic-updates.php. Accessed August 31, 2016.

18.

Lingani C, Bergeron-Caron C, Stuart JM, et al. Meningococcal meningitis surveillance in the African meningitis belt, 2004-2013. Clin Infect Dis. 2015;61(suppl 5):S410–5.CrossRefPubMedPubMedCentral

19.

Nnadi C, Oladejo J, Yennan S, et al. Large outbreak of Neisseria meningitidis Serogroup C—Nigeria, December 2016–June 2017. Morb Mortal Wkly Rep. 2017;66:1352–6.CrossRef

20.

Memish ZA, Yezli S, Almasri M, et al. Meningococcal serogroup A, C, W, and Y serum bactericidal antibody profiles in Hajj pilgrims. Int J Infect Dis. 2014;28:171–5.CrossRefPubMed

21.

Yezli S, Bin Saeed AA, Assiri AM, et al. Prevention of meningococcal disease during the Hajj and Umrah mass gatherings: past and current measures and future prospects. Int J Infect Dis. 2016;47:71–8.CrossRefPubMed

22.

Parker S. The Hajj: a constant travel destination amidst changing times. S Afr J Epidemiol Infect. 2010;25:14–8.

23.

Lingappa JR, Al-Rabeah AM, Hajjeh R, et al. Serogroup W-135 meningococcal disease during the Hajj, 2000. Emerg Infect Dis. 2003;9:665–71.CrossRefPubMedPubMedCentral

24.

Al-Mazrou YY, Al-Jeffri MH, Abdalla MN, Elgizouli SA, Mishskas AA. Changes in epidemiological pattern of meningococcal disease in Saudi Arabia. Does it constitute a new challenge for prevention and control? Saudi Med J. 2004;25:1410–3.PubMed

25.

Ceyhan M, Anis S, Htun-Myint L, et al. Meningococcal disease in the Middle East and North Africa: an important public health consideration that requires further attention. Int J Infect Dis. 2012;16:e574–82.CrossRefPubMed

26.

European Centre for Disease Prevention and Control. Invasive meningococcal disease. Available at: https://ecdc.europa.eu/en/publications-data/invasive-meningococcal-disease-annual-epidemiological-report-2015. Accessed February 13, 2018.

27.

Ladhani SN, Beebeejaun K, Lucidarme J, et al. Increase in endemic Neisseria meningitidis capsular group W sequence type 11 complex associated with severe invasive disease in England and Wales. Clin Infect Dis. 2015;60:578–85.CrossRefPubMed

28.

Stefanelli P, Miglietta A, Pezzotti P, et al. Increased incidence of invasive meningococcal disease of serogroup C, clonal complex 11, Tuscany, Italy, 2015 to 2016. Euro Surveill. 2016;21(12). https://doi.org/10.2807/1560-7917.ES.2016.21.12.30176.PubMedCrossRef

29.

Abad R, Lopez EL, Debbag R, Vazquez JA. Serogroup W meningococcal disease: global spread and current affect on the Southern Cone in Latin America. Epidemiol Infect. 2014;142:2461–70.CrossRefPubMed

30.

Husain EH, Barakat M, Al-Saleh M. Trends and variations in the epidemiology of meningococcal disease in Kuwait 1987-2013. J Infect Public Health. 2015;8:441–7.CrossRefPubMed

31.

Australian Government Department of Health. Invasive meningococcal disease national surveillance report. Available at: https://www.health.gov.au/internet/main/publishing.nsf/Content/5FEABC4B495BDEC1CA25807D001327FA/$File/19-June-2017-IMD-Surveillance-report.pdf. Accessed November 2, 2017.

32.

Australian Government Department of Health. Australian meningococcal surveillance programme annual report, 2015, vol. 40. Australia: Canberra ACT; 2016.

33.

New Zealand Ministry of Health. The epidemiology of meningococcal disease in New Zealand. Available at: https://surv.esr.cri.nz/PDF_surveillance/MeningococcalDisease/2013/2013AnnualRpt.pdf. Accessed November 2, 2017.

34.

Public Health Agency of Canada. Invasive meningococcal disease. Available at: http://www.phac-aspc.gc.ca/im/vpd-mev/meningococcal/professionals-professionnels-eng.php. Accessed November 2, 2017.

35.

Zhao J, Nelson TJ, Vu Q, Truong T, Stains CI. Self-Assembling NanoLuc luciferase fragments as probes for protein aggregation in living cells. ACS Chem Biol. 2016;11:132–8.CrossRefPubMed

36.

Centers for Disease Control and Prevention. Enhanced meningococcal disease surveillance report. Atlanta: GA; 2016.

37.

International Association for Medical Assistance to Travelers. World Immunization Chart. Available at: https://www.iamat.org/elibrary/view/id/1359. Accessed March 9, 2018.

38.

da Silva L, deTora L, Malerczyk C, Memish Z. Emergence of Neisseria meningitidis W-135 in the context of other rare serogroups. Clin Invest. 2012;2:177–88.CrossRef

39.

Public Health England. Meningococcal disease: laboratory confirmed cases in England and Wales; invasive meningococcal C infections by epidemiological year and age group, England (1998 and 1999–2014 and 2015). Available at: https://www.gov.uk/government/publications/meningococcal-disease-laboratory-confirmed-cases-in-england-and-wales. Accessed November 2, 2017.

40.

Campbell H, Parikh SR, Borrow R, et al. Presentation with gastrointestinal symptoms and high case fatality associated with group W meningococcal disease (MenW) in teenagers, England, July 2015 to January 2016. Euro Surveill. 2016;21:30175.CrossRef

41.

Lucidarme J, Hill DM, Bratcher HB, et al. Genomic resolution of an aggressive, widespread, diverse and expanding meningococcal serogroup B, C and W lineage. J Infect. 2015;71:544–52.CrossRefPubMedPubMedCentral

42.

Mueller JE, Gessner BD. A hypothetical explanatory model for meningococcal meningitis in the African meningitis belt. Int J Infect Dis. 2010;14:e553–9.CrossRefPubMed

43.

Hossain MJ, Roca A, Mackenzie GA, et al. Serogroup W135 meningococcal disease, The Gambia, 2012. Emerg Infect Dis. 2013;19:1507–10.CrossRefPubMedPubMedCentral

44.

Carville KS, Stevens K, Sohail A, et al. Increase in meningococcal serogroup W disease, Victoria, Australia, 2013–2015. Emerg Infect Dis. 2016;22:1785–7.CrossRefPubMedPubMedCentral

45.

Tsang RSW, Deeks SL, Wong K, Marchand-Austin A, Jamieson FB. Invasive serogroup W Neisseria meningitidis (MenW) in Ontario, Canada shows potential clonal replacement during the period January 1, 2009 to June 30, 2016. Available at: http://www.phac-aspc.gc.ca/publicat/ccdr-rmtc/16vol42/dr-rm42-12/ar-06-eng.php. Accessed March 27, 2017.

46.

Tsang R, Hoang LM, Tyrrell GJ, et al. Increase in Neisseria meningitidis serogroup W invasive disease in Canada: 2009–2016. Available at: https://www.canada.ca/en/public-health/services/reports-publications/canada-communicable-disease-report-ccdr/monthly-issue/2017-43/ccdr-volume-43-7-8-July-6-2017/increase-neisseria-meningitidis-serogroup-w-invasive-disease-canada-2009-2016.html. Accessed February 14, 2018.

47.

Doyle TJ, Mejia-Echeverry A, Fiorella P, et al. Cluster of serogroup W135 meningococci, southeastern Florida, 2008–2009. Emerg Infect Dis. 2010;16:113–5.CrossRefPubMedPubMedCentral

48.

49.

Ali A, Jafri RZ, Messonnier N, et al. Global practices of meningococcal vaccine use and impact on invasive disease. Pathog Glob Health. 2014;108:11–20.CrossRefPubMedPubMedCentral

50.

Nimenrix^®: EPAR—product information. European Medicines Agency. Available at: http://www.ema.europa.eu. Accessed July 28, 2017.

51.

Finne J, Leinonen M, Makela PH. Antigenic similarities between brain components and bacteria causing meningitis. Implications for vaccine development and pathogenesis. Lancet. 1983;2:355–7.CrossRefPubMed

52.

Trumenba^® (meningococcal group B vaccine). Full Prescribing Information, Wyeth Pharmaceuticals Inc., a subsidiary of Pfizer Inc, Philadelphia, PA, 2016.

53.

Folaranmi T, Rubin L, Martin SW, Patel M, MacNeil JR. Use of serogroup B meningococcal vaccines in persons aged ≥ 10 years at increased risk for serogroup B meningococcal disease: recommendations of the advisory committee on immunization practices, 2015. Morb Mortal Wkly Rep. 2015;64:608–12.

54.

European Medicines Agency. Committee for medicinal products for human use, summary of opinion: Trumenba. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/004051/WC500224394.pdf. Accessed March 9, 2018.

55.

Pfizer Canada. Trumenba, Product Monograph. Available at: http://www.pfizer.ca/sites/g/files/g10037206/f/201711/Trumenba_PM_195550_05-Oct-2017_E.pdf. Accessed March 9, 2018.

56.

Australian Government Department of Health. Prescription medicines: registration of new chemical entities in Australia. Available at: https://www.tga.gov.au/prescription-medicines-registration-new-chemical-entities-australia. Accessed March 9, 2018.

57.

Bexsero^® (meningococcal group B vaccine). Full prescribing information, Novartis, Cambridge, 2016.

58.

Bexsero^®. Summary of product characteristics. Siena, Italy: Novartis; 2013.

59.

Vernikos G, Medini D. Bexsero^® chronicle. Pathog Glob Health. 2014;108:305–16.CrossRefPubMedPubMedCentral

60.

European Medicines Agency. Bexsero. Available at: http://www.ema.europa.eu/ema/index.jsp?curl=pages/medicines/human/medicines/002333/human_med_001614.jsp. Accessed June 9, 2016.

61.

Australian Government Department of Health. The Australian immunisation handbook. 10th ed. Canberra: Australian Technical Advisory Group on Immunisation; 2015.

62.

Recommended schedule for the Expanded Program on Immunization, Bahrain. Kingdom of Bahrain Ministry of Health. Available at: https://www.moh.gov.bh/HealthInfo/Immunizations?lang=en. Accessed July 28, 2017.

63.

Government of Canada. Canadian immunization guide. Part 4. Active vaccines. Available at: https://www.canada.ca/en/public-health/services/publications/healthy-living/canadian-immunization-guide-part-4-active-vaccines.html. Accessed May 2, 2017.

64.

Ministry of Health Saudi Arabia. Health requirements for travellers to Saudi Arabia for pilgrimage to Makkah (2016/1437H Hajj) Available at: http://www.moh.gov.sa/en/Hajj/Pages/HealthRegulations.aspx. Accessed November 2, 2017.

65.

Public Health England. Meningococcal. The green book. London: Public Health England; 2015.

66.

MacNeil J, Meyer S. Meningococcal disease. Centers for Disease Control and Prevention. CDC health information for international travel 2016. New York: Oxford University Press; 2016.

67.

Public Health England. Meningococcal: The green book, Chapter 22. Available at: https://www.gov.uk/government/publications/meningococcal-the-green-book-chapter-22. Accessed November 2, 2017.

68.

World Health Organization. Standardization and validation of serological assays for the evaluation of immune responses to Neisseria meningitidis serogroup A/C vaccines. Geneva, 8-9 March 1999. Available at: http://apps.who.int/iris/bitstream/10665/66298/1/WHO_V%26B_99.19.pdf. Accessed April 4, 2016.

69.

Malaysian Society of Infectious Diseases and Chemotherapy. Guidelines for adult immunisation. 2nd edition. Available at: http://docplayer.net/14756999-Malaysian-society-of-infectious-diseases-and-chemotherapy-guidelines-for-adult-immunisation-2nd-edition.html. Accessed November 2, 2017.

70.

Saudia Arabia Ministry of Health. Meningococcal meningitis. Available at: https://www.moh.gov.sa/en/Hajj/HealthGuidelines/HealthGuidelinesDuringHajj/Pages/MeningococcalMeningitis.aspx. Accessed November 2, 2017.

71.

NIMENRIX (meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine). Summary of product characteristics, Pfizer Ltd, Sandwich, Kent, 2017.

72.

Bethea J, Makki S, Gray S, MacGregor V, Ladhani S. Clinical characteristics and public health management of invasive meningococcal group W disease in the East Midlands region of England, United Kingdom 2011 to 2013. Euro Surveill. 2016;21(24). https://doi.org/10.2807/1560-7917.ES.2016.21.24.30259.

73.

NIMENRIX (Meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine). Full prescribing information, Pfizer Australia Pty Ltd, West Ryde NSW, Australia, 2016.

74.

European Medicines Agency. Summary of Opinion (Menveo^®). Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Summary_of_opinion_-_Initial_authorisation/human/001095/WC500073647.pdf. Accessed November 2, 2017.

75.

Vesikari T, Forsten A, Boutriau D, et al. Randomized trial to assess the immunogenicity, safety and antibody persistence up to 3 years after a single dose of a tetravalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine in toddlers. Hum Vaccin Immunother. 2012;8:1892–903.CrossRefPubMedPubMedCentral

76.

Klein NP, Baine Y, Bianco V, et al. One or two doses of quadrivalent meningococcal serogroups A, C, W-135 and Y tetanus toxoid conjugate vaccine is immunogenic in 9- to 12-month-old children. Pediatr Infect Dis J. 2013;32:760–7.CrossRefPubMed

77.

Nimenrix^®, Summary of Product Characteristics (Meningococcal group A, C, W-135 and Y conjugate vaccine). Full prescribing information, Pfizer Ltd, Sandwich, Kent, 2018.

78.

Nimenrix^®, Product information (Meningococcal polysaccharide serogroups A, C, W-135 and Y conjugate vaccine). Full prescribing information, Pfizer Australia Pty Ltd, West Ryde NSW, 2016.

79.

Nimenrix Product Monograph (Meningococcal polysaccharide groups A, C, W-135 and Y conjugate vaccine). Full Prescribing information, Pfizer Canada Inc, Kirkland, 2016.

80.

Menveo^® Summary of Product Characteristics (Meningococcal (groups A, C, Y and W-135) oligosaccharide diphtheria CRM₁₉₇ conjugate vaccine). Full Prescribing Information, GSK Vaccines, Srl, Via Fiorentia, Italy, 2017.

81.

Menveo^® (Meningococcal (Groups A, C, Y and W-135) Oligosaccharide Diphtheria CRM197 Conjugate Vaccine). Full Prescribing Information, Novartis Vaccines and Diagnostics, Inc., Cambridge, MA, USA, 2013.

82.

Menveo^® Product Information (Meningococcal (Groups A, C, W-135 and Y) Oligosaccharide CRM197 Conjugate Vaccine). Full prescribing information, GlaxoSmithKline Australia Pty Ltd, Abbotsford, Victoria, 2017.

83.

Menveo^® Product Monograph (Meningococcal (Groups A, C, W-135 and Y) Oligosaccharide CRM197 Conjugate Vaccine). Full prescribing information, GlaxoSmithKline Inc., Mississauga, Ontario, 2017.

84.

Menactra^® (MCV4). Full prescribing information, Sanofi Pasteur, 2011.

85.

Menactra^® Australian Product Information (Meningococcal (Groups A, C, Y and W-135) Polysaccharide Diphtheria Toxoid Conjugate Vaccine). Full prescribing information, Sanofi-Aventis Australia Pty Ltd, Macquarie Park, NSW, 2014.

86.

Health requirements for travellers to Saudi Arabia for pilgrimage to Makkah (2017/1438 Hajj). Saudi Arabia Ministry of Health. Available at: http://www.moh.gov.sa/en/Hajj/Pages/HealthRegulations.aspx. Accessed July 28, 2017.

Title: A Review of Meningococcal Disease and Vaccination Recommendations for Travelers
Authors: Lidia C. Serra
Laura J. York
Amgad Gamil
Paul Balmer
Chris Webber
Publication date: 01-06-2018
Publisher: Springer Healthcare
Published in: Infectious Diseases and Therapy / Issue 2/2018
Print ISSN: 2193-8229
Electronic ISSN: 2193-6382
DOI: https://doi.org/10.1007/s40121-018-0196-z

Live Webinar | 27-06-2024 | 18:00 (CEST)

Keynote webinar | Spotlight on medication adherence

Reserve your place

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

WHO estimates that half of all patients worldwide are non-adherent to their prescribed medication. The consequences of poor adherence can be catastrophic, on both the individual and population level.

Join our expert panel to discover why you need to understand the drivers of non-adherence in your patients, and how you can optimize medication adherence in your clinics to drastically improve patient outcomes.

Prof. Kevin Dolgin

Prof. Florian Limbourg

Prof. Anoop Chauhan

Developed by: Springer Medicine

Obesity Clinical Trial Summary

At a glance: The STEP trials

A round-up of the STEP phase 3 clinical trials evaluating semaglutide for weight loss in people with overweight or obesity.

Developed by: Springer Medicine

Highlights from the ACC 2024 Congress

Year in Review: Pediatric cardiology

Pediatric Cardiology Video

Watch Dr. Anne Marie Valente present the last year's highlights in pediatric and congenital heart disease in the official ACC.24 Year in Review session.

Year in Review: Pulmonary vascular disease

Cardiopulmonary Comorbidity Video

The last year's highlights in pulmonary vascular disease are presented by Dr. Jane Leopold in this official video from ACC.24.

Year in Review: Valvular heart disease

Valvular Heart Disease Video

Watch Prof. William Zoghbi present the last year's highlights in valvular heart disease from the official ACC.24 Year in Review session.

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

ACC 2024 Congress Coverage

Year in Review: Heart failure and cardiomyopathies

Heart Failure Video

Watch this official video from ACC.24. Dr. Biykem Bozkurt discusses last year's major advances in heart failure and cardiomyopathies.

Watch now

Semaglutide benefits people with type 2 diabetes and obesity-related heart failure

16-04-2024 Type 2 Diabetes News

Incentivised to exercise

11-04-2024 Lifestyle Modifications News

New intervention for STEMI-related cardiogenic shock

10-04-2024 Myocardial Infarction News

» View more highlights on the ACC 2024 congress hub page

Image Credits

Illustration of figure on mountain summit/© Orapun / Stock.adobe.com, STEP AAG HeroTeaserCollection image/© Tarek / Generated with AI / Stock.adobe.com, ACC 2024 Pediatric and Congenital Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Pulmonary Vascular Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 Valvular Heart Disease: Year in Review/© 2024 American College of Cardiology, ACC 2024 HF and Cardiomyopathies: Year in Review/© 2024 American College of Cardiology, Woman out walking/© Seventyfour / stock.adobe.com (symbolic image with model), Woman checking smartwatch /© saltdium / stock.adobe.com (symbolic image with model), Cardiac catheterization/© Damian / stock.adobe.com

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Abstract

Funding

Please log in to get access to this content

Other articles of this Issue 2/2018

Population Pharmacokinetic Analysis of Asunaprevir in Subjects with Hepatitis C Virus Infection

Tenofovir-Associated Bone Adverse Outcomes among a US National Historical Cohort of HIV-Infected Veterans: Risk Modification by Concomitant Antiretrovirals

Delafloxacin: Place in Therapy and Review of Microbiologic, Clinical and Pharmacologic Properties

Correction to: Molecular Characterization of Pneumococcal Surface Protein A (PspA), Serotype Distribution and Antibiotic Susceptibility of Streptococcus pneumoniae Strains Isolated from Pakistan

Bactericidal and Virucidal Activity of Povidone-Iodine and Chlorhexidine Gluconate Cleansers in an In Vivo Hand Hygiene Clinical Simulation Study

A Review of Long-Term Toxicity of Antiretroviral Treatment Regimens and Implications for an Aging Population

Live: Thursday 27th June 2024, 18:00-19:30 (CEST)

Highlights from the ACC 2024 Congress

ACC 2024 Congress Coverage